Constrained de novo sequencing of neo-epitope peptides using tandem mass spectrometry
US20210020270A1 · Indiana University Bloomington · priority 2018
| Patent | US20210020270A1 ↗ |
| Status | Abandoned |
| Priority date | 2018-03-08 |
| Filed | 2019-03-08 |
| Published | 2021-01-21 |
| Assignee | Indiana University Bloomington |
| Claims | Constrained neo-epitope de novo sequencing |
| Also published as | WO2019173687A1 |
Abstract
Technologies for identifying one or more neoepitope peptides include generating a database that includes peptide sequences within a predefined range of length of residues, assigning a prior probability to each of the peptide sequences in the database, obtaining mass spectra of a plurality of fragments of a target molecule produced by mass spectrometry, determining, for each mass spectrum, matching scores of peptide-spectrum matches between the mass spectra and the peptide sequences in the database as a function of prior probabilities of the peptide sequences and matching probabilities, and determining a subset of the peptide-spectrum matches that has a corresponding matching score higher than a threshold.
Why it is here
Indiana University: constrained de novo sequencing of neo-epitope peptides, scoring every peptide of a length range under prior probabilities. Abandoned application; the inventors are the method paper’s authors.
Inventors (3)
Haixu Tang, Sujun Li, Alex DeCourcy
An inventor links to an author page only where the same person is evident, never on a name alone.
Catalogued patents it cites (1)
- US6582965B1 Method for de novo peptide sequence determination
Cited by (4 patent families, 4 organisations)
- Agilent Technologies company: WO2025042561A1
- Julius-Maximilians-Universität Würzburg academic: EP3896697A1
- 四川安迪科技实业有限公司 company: CN112714498B
- 杭州纽安津生物科技有限公司 company: CN114705796B
Every family, of any applicant, that cites this one, as Google Patents lists them; an assignee is given its English name.